Altimmune to Present at Upcoming Investor Conferences

September 30, 2020 at 7:00 AM EDT

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

  • H.C. Wainwright 4th Annual NASH Investor Conference
    Monday, October 5, 20203:30 pm ET
  • Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
    Monday, October 5, 20204:45 pm ET

The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at under Events/Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit

Investor Contacts:

Stacey Jurchison Ashley R. Robinson
Altimmune, Investor Relations LifeSci Advisors, LLC
Phone: 410-474-8200 617-430-7577

Altimmune Logo.png

Source: Altimmune, Inc.


Investor Contact

Will Brown
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail